IRD (Opus Genetics) Interest Expense : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Opus Genetics's interest expense for the three months ended in Dec. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Opus Genetics's Operating Income for the three months ended in Dec. 2024 was $ -10.03 Mil. Opus Genetics's Interest Expense for the three months ended in Dec. 2024 was $ 0.00 Mil. Opus Genetics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Opus Genetics Interest Expense Historical Data

The historical data trend for Opus Genetics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Interest Expense Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-6.85

-0.01

-1.33

Opus Genetics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Opus Genetics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Opus Genetics (NAS:IRD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Opus Genetics's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-10.03 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.00 Mil.

Opus Genetics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Opus Genetics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Opus Genetics Inc has no debt.

Opus Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (NAS:IRD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

R3X1:Germany

Address

8 Davis Drive, Suite 220, Durham, NC, USA, 27709

Website

https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Executives

George Magrath	officer: Chief Executive Officer	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel	officer: SVP, Operations & Bus. Dev.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch	director, officer: President and CEO	17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J	director	5130 ROUTE 212, WILLOW NY 12495
Jay Pepose	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton	director	3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba	officer: VP of Finance	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher	director	6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer	director
Sean Ainsworth	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann	officer: VP of Corp. Dev. & Ops & Sec.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price	director	8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky	officer: President and CFO	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732